GPR119抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: K562 cell lysate , Primary antibody: P06590(GPR119 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06590(GPR119 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06590(GPR119 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

GPR119 (G Protein-Coupled Receptor 119) is a class A GPCR predominantly expressed in pancreatic β-cells and intestinal L-cells, where it plays a role in glucose homeostasis and energy metabolism. It is activated by endogenous lipid-derived ligands, such as oleoylethanolamide (OEA) and 2-monoacylglycerol, which stimulate insulin secretion from pancreatic β-cells and glucagon-like peptide-1 (GLP-1) release from intestinal cells. This dual action makes GPR119 a therapeutic target for type 2 diabetes and obesity.

GPR119 antibodies are critical tools for studying its expression, localization, and signaling mechanisms. They are used in immunoassays (e.g., Western blotting, immunohistochemistry, flow cytometry) to quantify receptor levels in tissues or assess its regulation under metabolic conditions. Both polyclonal and monoclonal antibodies have been developed, often targeting extracellular or intracellular epitopes to study receptor trafficking or ligand interactions. Challenges in antibody development include GPR119's low endogenous expression and structural homology with other GPCRs, requiring rigorous validation to ensure specificity.

Research using GPR119 antibodies has clarified its role in nutrient-sensing pathways and informed drug discovery efforts, including the design of GPR119 agonists. However, clinical trials of such agonists have shown mixed results, highlighting the need for deeper mechanistic insights. Reliable antibodies remain essential for unraveling GPR119's physiology and optimizing therapeutic strategies.